Chinese contract development and manufacturing organisation with its main site at Wuxi in Jiangsu and further sites in Shanghai and at Leiden in the Netherlands, spun out of the WuXi group and listed in Hong Kong in 2023. Specialises in antibody drug conjugates and other bioconjugates, providing discovery and development of linkers and payloads, antibody and conjugate process development, analytical development and quality control, and manufacture of drug substance and sterile drug product for clinical and commercial supply.
댓글이 없습니다.
평가 & 댓글 남기기